Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Frost & Sullivan Commends Millipore’s Success in Developing Mammalian Gene Expression UCOE Technology

Published: Monday, December 10, 2007
Last Updated: Monday, December 10, 2007
Bookmark and Share
Millipore announced to be the recipient of the 2007 Frost & Sullivan Technology Innovation of the Year Award in the U.S. Drug Discovery Technologies market.

Frost & Sullivan selects Millipore Corporation’s Ubiquitous Chromatin Opening Element (UCOE™) gene expression technology as the recipient of the 2007 Frost & Sullivan Technology Innovation of the Year Award in the U.S. Drug Discovery Technologies market.

Millipore’s approach for mammalian gene and protein expression offers significant benefits to manufacturers of biologic-based medicines, as there is high demand for these drugs because they are required for patients diagnosed with cancer and other diseases.

The UCOE™ technology exploits the principles guiding the expression of housekeeping genes, primarily their constitutively active state, in order to have high expression of transgenes that have been incorporated into a cell’s genome.

Due to the responsibility to maintain the cellular environment, housekeeping genes are endowed with a chromatin region that is always open to the cell’s translation machinery, and the UCOE technology uses a novel approach that harnesses these key regulatory DNA elements associated with the housekeeping genes to perform a similar function when incorporated with proprietary expression vectors.

Because of its chromatin-localization-independent high level expression, UCOE™ technology aids isolation of highly productive clonal lines by screening nearly 100 clones in less than four months, which is significantly faster than the gene amplification-based program of conventional technologies that requires as much as 12-15 months. The cell lines generated with UCOE™ are stable for at least 130 generations, which roughly corresponds to 130 days for CHO cells.

“Overall, protein expression levels are shown to be 10-50 fold higher when using Millipore’s UCOE technology then those obtained through conventional mammalian protein expression methods,” says Frost & Sullivan Industry Analyst Shankar Sellappan, Ph.D. “These elevated expression levels are achieved by significantly higher specific productivity rates resulting from robust transcriptional activity in UCOE™-controlled transcriptionally unrestricted chromatin sites.”

A significant advantage of the UCOE™ technology is that it catalyzes increased yields of recombinant proteins from both pools and clones, and enables production of gram-level quantities of protein from stable pools in less than two months. This allows for effortless generation of research material early on during a drug developmental program, and supports the toxicology study efforts that can be performed in parallel.

“Having established itself as a leader in separations methodologies, Millipore has successfully entered the growing market for protein expression products in the biopharmaceutical industry,” notes Dr. Sellappan. “Millipore’s innovative approach dramatically improves the quality of research, while its UCOE™ technology is expected to have a lasting impact on both drug discovery efforts and the development and manufacturing of therapeutic drugs.”

Millipore continues to refine the UCOE™ technology by improving the vector architecture in order to provide a more efficient and robust transcriptional and translational performance.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellular Reprogramming – What the Future Holds
Advancements in cellular reprogramming are coming at a furious pace. Along with these scientific breakthroughs come new opportunities for the development of therapeutics, disease modeling, drug screening, and new pathways to personalized medicine.
Friday, July 23, 2010
Millipore Expands Drug Discovery and Development Services with BioAnaLab Acquisition
Acquisition extends Millipore’s biopharmaceutical services offering to European market.
Tuesday, August 11, 2009
Millipore Opens new Bioprocess Manufacturing Facility in Massachusetts
New facility will produce company’s Mobius® single-use product line used for biopharmaceutical manufacturing technologies.
Wednesday, June 10, 2009
Millipore and UMass Lowell Dedicate the Millipore Process Development Laboratory
Millipore announced the opening of the Millipore Corporation Process Development Laboratory in partnership with the university.
Friday, April 10, 2009
Millipore Announces Technology Acquisition to Strengthen Drug Discovery Product Offering
The purchase of Epitome Biosystems’ EpiTag™ technology assets will accelerate development of multiplex immunoassays for cell signaling.
Monday, March 02, 2009
Millipore Extends Exclusive License Agreement with University of Dundee
The ongoing collaboration will bring novel cell signaling tools and services to life science researchers worldwide.
Friday, October 10, 2008
ReNcell® VM Neural Stem Cell Line Models Parkinson’s Disease
Milipore announces the publication of a new discovery derived from its ReNcell VM neural stem cell line.
Tuesday, July 22, 2008
Millipore Unveils Expanded Drug Discovery Development Facility
The $3.4 million expansion will enable Millipore to keep pace with the growth of its worldwide drug discovery and development business.
Monday, June 30, 2008
Millipore Launches Progenitor Cell-Enriched Primary Human Epithelial Cell Cultures
According to Company, these primary cell cultures are designed to provide an enriched population of progenitor cells from skin, cornea, and bladder epithelia.
Friday, April 18, 2008
Millipore Launches Antibody Learning Center
The web tool is designed for navigating company’s antibody portfolio and planning efficient workflows for immunodetection in protein research.
Wednesday, April 16, 2008
Millipore Corporation and Novozymes Form Strategic Alliance to Supply Animal-Free Cell Culture Supplements for Bioprocessing
Alliance will accelerate launch of new animal-free supplements and provide customers with a source of high performance cell culture products.
Tuesday, December 18, 2007
Millipore Announces Stem Cell Tested Initiative
Millipore’s Stericup with Express PLUS membrane is the first available under this initiative.
Wednesday, December 05, 2007
Millipore Launches new Website
Improved functions include product information, ordering and support.
Wednesday, October 31, 2007
Millipore Corporation Announces new ReNcell® Data from Collaboration with ReNeuron
Millipore releases new data concerning its ReNcell neural stem cell lines at the ISSCR meeting in Cairns, Australia on June 20, 2007.
Thursday, June 21, 2007
Millipore Announces Kinase Screening Agreement with Johnson & Johnson Pharmaceutical Research & Development
J&JPRD to supply potential protein kinase inhibitors for kinase selectivity profiling against Millipore's panel of 252 protein and lipid kinases.
Wednesday, January 17, 2007
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!